18 results about "Homocysteine" patented technology

The invention discloses an amine-terminated acrylamide polymer shale inhibitor and a preparation method thereof. Polymeric monomers of the inhibitor comprise an acrylamide monomer A, N, N-dimethylacrylamide, acryloyl morpholine and an amino thiol monomer. The acrylamide monomer A is selected from at least one of methacrylamide, isopropyl acrylamide and acrylamide; the amino thiol monomer is selected from at least one of cysteine and homocysteine. The synthesis process is simple and efficient, the cost is low, and the prepared polyamine inhibitor is high in shale hydration inhibition, stable in performance under the high-temperature condition and good in compatibility.

A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

The invention discloses a gastrointestinal tumor patient postoperative weakness risk correlation analysis method and system fused with a co-disease map, and belongs to the field of medical care informatics, and the method comprises the following steps: obtaining clinical pathological characteristics, co-disease assessment, serum biomarkers and social and psychological assessment scale data of gastrointestinal tumor patients; obtaining statistical effect values of homocysteine and health attainment, and executing isomorphic mapping; identifying a chained intermediary conduction path and generating a coupling strength factor, and performing weighted correction on the initialized weight matrix; inputting the multi-source data as a risk source excitation signal into the atlas, executing correction calculation, and outputting a risk prediction score; a maximum weight subgraph search is performed to generate risk attribution analysis data. According to the method, the multi-dimensional heterogeneous association map is constructed to fuse the multi-source data of the patient and the medical priori knowledge, and the risk conduction is quantified through the path topology analysis and the matrix correction operation, so that the accurate prediction of the postoperative weakness risk and the interpretable attribution of the key pathogenic path can be realized.

The invention belongs to the technical field of synthetic biology, and particularly relates to a genetically engineered bacterium for high yield of L-methionine as well as a construction method and application of the genetically engineered bacterium. By strengthening the hemC gene, the utilization capacity of escherichia coli on a sulfur source is improved; by strengthening the malY gene and the multi-copy metB gene, the capability of converting cysteine into homocysteine in the escherichia coli is improved; by knocking out an mnaT gene and introducing metA to a genome to resist feedback, the degradation of L-methionine is reduced, and meanwhile, the supply of a precursor O-succinyl homoserine is increased; and finally, a pAmZK plasmid is introduced to obtain the escherichia coli genetically engineered bacterium strain with high yield of L-methionine, and the yield is increased from 3.21 g / L to 3.67 g / L. And fed-batch fermentation is carried out in a 5L tank in a pH feedback feeding manner, the yield reaches 43.55 g / L within 64 hours, and a research foundation is laid for production of L-methionine by a microbiological method.

The invention discloses a cardiovascular event risk index calculation method, and relates to the technical field of medical information, and the method comprises the following steps: determining whether a to-be-evaluated patient meets an application condition or not according to a preset inclusion standard; for a patient meeting the standard, collecting a peripheral blood sample of the patient, carrying out centrifugal treatment, and separating to obtain a serum or plasma sample; s2, quantitatively measuring four serological indexes, namely lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, homocysteine and serum amyloid protein A, of the serum or plasma sample obtained in the step S1 by using an authenticated laboratory detection method; s2, calculating a cardiovascular risk index by using a cardiovascular risk calculation formula based on the four index values measured in the step S2; s3, according to the cardiovascular risk index value calculated in the step S3, dividing the cardiovascular event risk of the patient into three levels of low risk, medium risk and high risk; and S4, generating a structured risk assessment report according to the risk grading result obtained in the step S4, and outputting the structured risk assessment report.

The invention discloses application of S-adenosylhomocysteine in preparation of a medicine for treating neuromuscular diseases, and belongs to the technical field of medicines. The invention discloses a novel pharmaceutical application of S-adenosine homocysteine in preparation of drugs for treating neuromuscular diseases for the first time. Mechanism research finds that S-adenosylhomocysteine can enhance the ability of a Trmt61a / 6 compound to bind unmethylated tRNA and inhibit abnormal interaction between CMT2 pathogenic mutant protein and stress particle core protein, so that the ability of motor neurons to resist external stress is enhanced, and the S-adenosylhomocysteine has the effects of improving peripheral nerve and muscle lesions of neuromuscular diseases, improving the immunity of the motor neurons and improving the immunity of the motor neurons. And the potential of motor nerve dysfunction. The invention provides a direction for new clinical application of the S-adenosyl homocysteine. The invention provides possibility for preparing novel medicines for treating neuromuscular diseases.

The invention belongs to the technical field of biology, and particularly relates to application of a reagent for inhibiting an FOXO3a gene in preparation of a medicine for treating homocysteine induced metabolism-related fatty liver disease, and the base sequence of the FOXO3a gene is shown as SEQ ID NO.1. According to the application, Western blot is used for analyzing high methionine diet induced Cbs < + / -> mouse liver tissues and Hcy treatment group liver cells, it is clear that the expression of FOXO3a in the Hcy induced metabolism-related fatty liver diseases is remarkably up-regulated, and it is clear that FOXO3a can influence the occurrence of the metabolism-related fatty liver diseases through mediating mitochondrial damage.

The invention provides application of a ratiometric fluorescent probe for high-selectivity detection of colorectal cancer marker homocysteine for tumor diagnosis, and relates to the field of analytical chemistry. The structural formula of the ratiometric fluorescent probe is shown in the specification. The ratio fluorescent probe adopts a double binding site strategy, nitryl is introduced into a coumarin fluorophore to realize specific detection of homocysteine, and meanwhile, a chromophore with strong green fluorescence is connected through piperazine, so that ratio detection of homocysteine is realized. Potential interference of background fluorescence can be avoided through the ratio of red fluorescence to green fluorescence, so that the sensitivity and precision of homocysteine detection are improved. In addition, the probe has the advantages of good selectivity, good biocompatibility and the like when being used for detecting homocysteine, and has a huge application prospect in the technical fields of analytical chemistry, life science, biomedical treatment and the like.

Provided in the present application is a ratiometric fluorescent probe for detecting a colorectal cancer marker homocysteine with high selectivity and a preparation method thereof and relates to the field of analytical chemistry. The ratiometric fluorescent probe has structural formula of:Dual-site binding strategy is adopted in the ratiometric fluorescent probe and the nitro group is introduced into the coumarin fluorophore to achieve specific detection of homocysteine, at the same time, ratiometric detection of homocysteine is achieved by connecting a chromophore having strong green fluorescence through piperazine. Potential interference of background fluorescence can be avoided by the ratio of red fluorescence to green fluorescence, thereby enhancing the sensitivity and accuracy of homocysteine detection. In addition, the probe has the advantages of good selectivity and biocompatibility in detecting homocysteine, and has great application prospects in technical fields such as analytical chemistry, life sciences and biomedicine.

The present application relates to the technical field of biological medicine, and particularly relates to a histidine methyltransferase METTL9 inhibitor and a screening method, a reaction system and application thereof.The screening method comprises the following steps: S1, constructing a histidine methyltransferase METTL9 reaction system; S2, dividing the reaction system into a test system and a control system, adding S-adenosylhomocysteine hydrolase and a fluorescent dye capable of undergoing an addition reaction with homocysteine and causing a change in fluorescence signal; S3, adding a candidate compound to the test system, and not adding the candidate compound to the control system, and detecting the fluorescence signals of the test system and the control system; and S4, determining whether the candidate compound is a METTL9 inhibitor based on the fluorescence signals.The screening method couples the enzymatic reaction with the fluorescence signal transduction, has the advantages of high sensitivity, simple operation, good safety, low cost and being particularly suitable for automatic high-throughput screening.

The application discloses a preparation method and application of S-adenosyl-methyl cysteine, and the preparation method comprises the following reaction: S-adenosyl-L-cysteine is methylated by using a first methyltransferase or a first methyltransferase mutant and a methyl donor to obtain S-adenosyl-methyl cysteine; or S-adenosyl-L-homocysteine is methylated by using a methyltransferase or a first methyltransferase mutant and a methyl donor to obtain S-adenosyl-methionine. The method has the characteristics of low cost and simple operation, and enables S-adenosyl-methyl cysteine to replace expensive S-adenosyl methionine (SAM) as a coenzyme and a methyl donor in a methylation reaction, and is applied to methylation modification of natural products based on a coenzyme regeneration system.

The present application relates to the technical field of metabolite detection, and particularly relates to a method and a kit for detecting homocysteine and metabolically related substances. The present application provides a method for detecting homocysteine and metabolically related substances, comprising the following steps: mixing the to-be-detected sample, S1-S6 standard, high-value quality control and low-value quality control with reagent D respectively, standing, then mixing with a reducing agent for reaction, and then mixing with a formic acid acetonitrile solution to obtain a mixture; mixing the mixture with water, centrifuging, taking the supernatant for liquid chromatography-tandem mass spectrometry detection. The method can detect three types of compounds including homocysteine, cysteine and methionine indicators at one time, and comprehensively reflects the reasons for the increase of homocysteine.

The invention belongs to the technical field of preparation of in-vitro diagnostic products, and particularly relates to homocysteine competition method immunochromatography test paper based on an antigen-antibody complex specific antibody, a kit and application of the homocysteine competition method immunochromatography test paper and the kit. The homocysteine competition method immunochromatography test paper comprises a quality control line coated with an antibody and a detection line coated with an S-(5 '-adenosine)-L-cysteine and bovine serum albumin coupling antigen, wherein the antibody is a compound antibody of a solid phase carrier marked by an (S-(5 '-adenosine)-L-cysteine monoclonal antibody and an (S-(5'-adenosine)-L-cysteine monoclonal antibody, and the (S-(5 '-adenosine)-L-cysteine monoclonal antibody and the (S-( The compound antibody is obtained by compounding S-(5 '-adenosine)-L-cysteine serving as an antigen and a solid-phase carrier labeled by an S-(5'-adenosine)-L-cysteine monoclonal antibody, immunizing and purifying. According to the homocysteine competition method immunochromatography test paper provided by the invention, negative correlation linkage of the C line signal intensity and the T line is realized, the dynamic range of the T / C ratio is widened, and the homocysteine detection precision is improved.

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, dimethylglycine, tryptophan, indoxylsulfate, phenylacetylglutamine, sialic acid, 5-hydroxy-6-indolyl-o-sulfate, 5-(Δ-carboxybutyl) homocysteine, and / or an anion having m / z:RMT:polarity of 345.1553:0.770:n, or determination of metabolites in stool samples, such as ketodeoxycholic acid, cholic acid, choline, tryptophan, trimethyllysine, serine, butyric acid, lactic acid, hypoxanthine and / or guanine.

The application discloses application of a piRNA-145836 preparation in preparation of a medicine for preventing and treating type 2 diabetes induced by high homocysteine, and belongs to the technical field of biological medicine and molecular biology. The nucleotide sequence of the piRNA-145836 is shown as SEQ ID No. 1. The piRNA-145836 can play a key role in type 2 diabetes induced by high homocysteine, and can regulate a mechanism, promote recovery of pancreatic function, restore insulin secretion capacity, reduce abnormal activation of copper death-related proteins, reduce accumulation of copper ions in islet beta cells, and improve sugar metabolism disorder induced by high homocysteine. The application solves the technical problems of lack of cognition of the role of piRNA in copper ion homeostasis and beta cell fate determination, ambiguity of the role target of resveratrol, and unknown expression regulation mechanism of key copper transport proteins in a high homocysteine environment in the prior art.

The invention provides a preparation method of a cross-linked polymer-GalNT1 siRNA nano compound and application of the cross-linked polymer-GalNT1 siRNA nano compound in tumor immunotherapy, and belongs to the technical field of biological medicine. According to the invention, the homocysteine modified cationic polymer and the homocysteine modified zwitterionic polymer are introduced into the nano-composite, so that the consumption of serine in tumor tissues or tumor cells is realized, and the inhibition effect of GalNT1 siRNA on Tn antigens is enhanced. The nanocomposite can effectively cope with the problem of insufficient tumor immune infiltration caused by abnormal expression of Tn antigens, can respond to reducing substances in a colorectal cancer microenvironment, improves the targeting of tumor treatment, further enhances immune infiltration in tumors, relieves the immunosuppression of tumor tissues and reduces the metastasis capacity of tumor cells. The nano-composite has important significance and wide application prospect in the field of tumor treatment.

This invention discloses a rapid SERS method for detecting homocysteine. The main steps of this method are as follows: (1) enhancing the synthesis of nanoparticles; (2) reducing all homocysteine ​​in plasma and detecting its total amount; (3) collecting standard SERS spectra; (4) fitting curves; (5) quantitative detection of SERS: homocysteine ​​is detected using a Raman spectrometer to obtain its standard spectrum, and a series of concentration standard curves are obtained according to step (4) to quantitatively detect the concentration of homocysteine ​​in the sample. The method provided by this invention is simple to operate, low in cost, and fast. It does not require the use of large-scale precision detection and analysis instruments and can realize on-site detection. It does not require professional technicians to operate, and the professional knowledge requirements of the detection personnel are not high. Ordinary people can quickly master the method by following the procedure, which greatly saves time and cost.

The invention discloses a space-time resolution single cell m6A dynamic modification analysis method and application thereof, and the method comprises the following steps: 1, using propargyl-L-selenium homocysteine (PSH) to carry out metabolism labeling on living cells, so that the m6A modification site newly modified by RNA is specifically introduced into a propargyl functional group; 2, covalently linking a DNA probe with an azide group to the propargyl functional group through a click chemical reaction; step 3, performing signal amplification on the DNA probe through an adjacent connection and rolling circle amplification technology; and 4, carrying out space imaging by adopting a fluorescence in-situ hybridization or fluorescence in-situ sequencing technology so as to realize space-time dynamic analysis on m6A modification in the single cell. The method disclosed by the invention has space-time resolution capability on m6A dynamic modification.